Tran, CT and Leiper, JM and Vallance, P (2003) The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements , 4 (4) 33 - 40.
Full text not available from this repository.
An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminohydrolase (DDAH) enzymes metabolise ADMA. We and others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH enzymes and its role in the regulation of nitric oxide generation
|Title:||The DDAH/ADMA/NOS pathway|
|Additional information:||DA - 20031210 IS - 1567-5688 LA - eng PT - Journal Article PT - Review PT - Review, Tutorial RN - 0 (Enzyme Inhibitors) RN - 30315-93-6 (N,N-dimethylarginine) RN - 74-79-3 (Arginine) RN - EC 18.104.22.168 (Nitric-Oxide Synthase) RN - EC 3.5. (Amidohydrolases) RN - EC 22.214.171.124 (dimethylargininase) SB - IM|
|Keywords:||activity, advances, Amidohydrolases, analogs & derivatives, Animals, Arginine, Blood Pressure, cytology, DETERMINANT, disease, drug effects, endothelial cells, Endothelium, Vascular, enzyme, Enzyme Inhibitors, Enzymes, function, GENERATION, IM, in vivo, in-vivo, INDICATE, INHIBITOR, INHIBITORS, LA, LEVEL, literature, metabolism, nitric oxide, nitric oxide synthase, NITRIC-OXIDE, Nitric-Oxide Synthase, NOS, NUMBER, Other, OXIDE, PATHWAY, pharmacology, physiology, physiopathology, Recent Advances, regulation, report, Review, STATE, STATES, Support, Non-U.S.Gov't, SYNTHASE, Vasodilation, vivo|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only: edit this record